Lilly Looks To Tackle High Lipoprotein(a) Via Gene Editing With Verve

 
• By Joseph Haas
Gene editing
Lilly is teaming with Verve in cardiovascular gene-editing therapy • Source: Shutterstock

More from Deals

More from Business